NCT lookup

Inclusion Criteria:

* Men and/or Women;
* 18 to 55 years old;
* Phototypes I to VI according to the Fitzpatrick classification;
* Subjects of any ethnicity according to Brazilian Institute of Geography and Statistics (IBGE) criteria
* Integral skin in the test areas;
* Subjects with oily skin, confirmed by instrumental measurements: (sebumetry value of at least 100μg/cm² in the frontal region (average of 3 measurements)).
* Subjects with face oil shine - confirmed by Dermatologist;
* Subjects with enlarged pores on the face - confirmed by a Dermatologist;
* Subjects with self-perceived combination/oily or very oily skin on the face;
* Subjects with a self-perceived oil shine on the face;
* Subjects with self-perceived enlarged pores on the face;
* Do not use cosmetic products (including usual soap) the night before the visit and do not wash your face after 10 p.m. the day before the visit;
* For male subjects: who agree to shave 48 hours before the visits;
* Generally, in good health based on medical history reported by the subject;
* Subjects able to read, write, speak, and understand Portuguese;
* Agreeing to adhere to the procedures and requirements of the study and attending the Site on the day(s) and time(s) set for the evaluations;
* Subjects who signed the terms Informed Consent Document (ICD) and Informed Consent Image Disclosure (ICID);
* Intends to complete the study and is willing and able to follow all the study instructions.

Exclusion Criteria:

* Has known allergies or adverse reactions to common topical skin care products including sunscreens;
* Presents a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
* Have primary/secondary lesions (e.g. scars, ulcers, vesicles) or tattoos in the test areas;
* Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication;
* Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:

  * Immunosuppressive or steroidal drugs within 2 months before Visit 1\*
  * Non-steroidal anti-inflammatory drugs within 5 days before Visit 1\* (For Oxaprozin and Piroxicam consider 2 weeks before visit 1).
  * Antihistamines within 2 weeks before Visit 1\* \*If an individual is taking one of these medication types, the individual is not considered eligible at screening. However, if a subject begins using one of these medications during the study, the Study Physician should be consulted to consider the impact of the specific medication on subject safety and/or the study results, as described in section "Concurrent/Concomitant Medication".
* Use of any other products capable of interfering with the study evaluations, at the discretion of the dermatologist;
* Subjects who have undergone invasive aesthetic or dermatological treatment in the test area within 2 months prior to the start of the study or during the study;
* Subjects who had used cosmetic products to treat oiliness/shine on the same area (face) within 14 days prior to the start of the study;
* Subjects who are using any medication to treat diseases of the face or eyes;
* Subjects who reported being pregnant, or planning to become pregnant during the study;
* Has a history of or a concurrent health condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study;
* Simultaneously taking part in another study;
* Being an employee/contractor or close relative of the Principal Investigator, Study Site, or Sponsor;
* Excessive hair in the assessment area that could interfere with instrumental measurements.

• Campinas, São Paulo, Brazil